Canaccord analyst Kyle Mikson raised the firm’s price target on 10x Genomics (TXG) to $16 from $15 and keeps a Buy rating on the shares. The firm said it remains one of their favored names in Tools after a solid 2Q25, as they are optimistic that the company can reaccelerate growth in the relative near term and view the shares as attractive at current levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics Positioned for Growth: Strong Q2 Results, Strategic Acquisition, and Optimistic Outlook Drive Buy Rating
- 10x Genomics price target raised to $13 from $12 at UBS
- 10x Genomics price target raised to $14 from $10 at Deutsche Bank
- 10x Genomics: Balanced Outlook Amid Growth and Uncertainties
- 10x Genomics price target raised to $15 from $13 at Barclays